Collectively, these findings support sex-aware therapeutic strategies that combine modulation of neuron–glioma coupling with chromatin, receptor tyrosine kinase, and angiogenic targets, and they provide biomarkers for near-term validation in experimental models. The gene discussed is NTRK1; the disease is glioma.